GlassScriptPhysician profile
Samuel Bosco
NPI 1043847833
$4,598.29
in general payments reported to CMS, 2019-2025
13 companies · $3,199 in 2025
The $3,199 reported for 2025 was more than what 94% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $136 · 2022: $448 · 2023: $375 · 2024: $440 · 2025: $3,199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,043 · Travel and Lodging: $1,971.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,043.00 |
| Travel and Lodging | $1,971.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $2,857.99 | 2024-2025 | Inspire |
| Genzyme Corporation | $497.56 | 2021-2024 | |
| Stryker Corporation | $260.36 | 2022-2023 | Scopis Ent |
| Regeneron Healthcare Solutions, INC. | $240.95 | 2021-2025 | Dupixent |
| Integra Lifesciences Corporation | $229.58 | 2022-2025 | Inspira Air, Acclarent Aera, Trudi Probe |
| Phathom Pharmaceuticals, INC. | $124.74 | 2024 | Voquezna |
| Medtronic, INC. | $111.08 | 2022-2025 | Stealthstation S8 Platform, Nuvent |
| Smith+Nephew, INC. | $68.07 | 2022-2024 | Tula |
| Optinose US, INC. | $56.38 | 2025 | |
| Depuy Synthes Sales INC. | $49.70 | 2025 | Matrixmandible, Trumatch |
| Aerin Medical INC. | $40.02 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.83 | 2023 | Elaprase |
| Glaxosmithkline, LLC. | $26.03 | 2023 | Nucala |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Bosco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.